Back

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation III Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Denis Xavier

St John's Medical College Hospital, Bangalore (India)

24 More presentations in this session

Presentation thumbnail
Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers
Doctor C. Gatti (Ravenna, IT)
Abstract Slides
Presentation thumbnail
High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation
Doctor D. Iglesias (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation
Doctor J. Wieczorek (Katowice, PL)
Abstract Slides
Presentation thumbnail
Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation
Doctor A. Parwani (Berlin, DE)
Presentation thumbnail
Recalibration of CHA2DS2-VASc with an age category (50-64 years) enhances stroke risk stratification in chinese patients with atrial fibrillation
Doctor P. Chan (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation III

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources